LENVATINIB for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 3,849 adverse event reports in the FDA FAERS database where LENVATINIB was used for Renal cell carcinoma.
Most Reported Side Effects for LENVATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 4,262 | 12.6% | 321 | 2,714 |
| Hypertension | 4,152 | 12.3% | 405 | 2,522 |
| Fatigue | 3,603 | 10.7% | 208 | 2,023 |
| Decreased appetite | 3,257 | 9.7% | 363 | 2,209 |
| Malignant neoplasm progression | 2,929 | 8.7% | 1,549 | 1,298 |
| Nausea | 2,492 | 7.4% | 160 | 1,637 |
| Blood pressure increased | 2,228 | 6.6% | 104 | 1,411 |
| Vomiting | 1,962 | 5.8% | 122 | 1,458 |
| Asthenia | 1,643 | 4.9% | 122 | 1,180 |
| Malaise | 1,602 | 4.7% | 241 | 989 |
| Weight decreased | 1,529 | 4.5% | 106 | 901 |
| Dehydration | 1,526 | 4.5% | 97 | 1,375 |
| Pyrexia | 1,438 | 4.3% | 134 | 1,149 |
| Hypothyroidism | 1,375 | 4.1% | 165 | 698 |
| Headache | 1,268 | 3.8% | 50 | 810 |
Other Indications for LENVATINIB
Endometrial cancer (6,770)
Hepatocellular carcinoma (5,384)
Renal cancer (2,862)
Thyroid cancer (2,668)
Uterine cancer (2,233)
Hepatic cancer (1,017)
Clear cell renal cell carcinoma (935)
Product used for unknown indication (916)
Papillary thyroid cancer (501)
Renal cell carcinoma stage iv (442)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)
CABOZANTINIB (1,241)